文献速递关节外科创伤骨科

阶梯式增强肩胛盂组件在解剖型全肩关节置换术治疗B2和B3型肩胛盂病变中的早期疗效研究

Stepped Augmented Glenoid Component in Anatomic Total Shoulder Arthroplasty for B2 and B3 Glenoid Pathology: A Study of Early Outcomes.
PubMed 文献 · J Bone Joint Surg Am · 2021-01-01

结果显示,B3肩胛盂使用增强组件时中心peg骨溶解(CPO)发生率(29%)高于A1使用标准组件(5%)(p=0.028),而B2与A1之间无显著差异;三组术后肩胛盂假体版本角和倾斜角无差异,但B3组假体内移更明显(p<0.001)。

要点

  • 阶梯式增强肩胛盂组件可用于B2型肩胛盂骨缺损,短期疗效与A1型无骨缺损者相当。
  • B3型肩胛盂使用增强组件后中心peg骨溶解风险较高(29% vs A1的5%,p=0.028)。
  • B3型肩胛盂术后假体相对病前关节线内移更显著(p<0.001)。

核心结论

  • 阶梯式增强肩胛盂组件可恢复B2型肩胛盂的解剖形态,短期临床和影像学结果与A1型使用标准组件相当。
  • 对于中重度B3型肩胛盂病变,使用该增强组件发生中心peg骨溶解的风险更高。

研究设计与样本

  • 术前、术后3个月内(金属伪影减少技术)及术后至少2年进行序列三维CT扫描,通过肩胛盂和植入物三维配准测量植入物位置、偏移和中心peg骨溶解。

主要发现

  • B3肩胛盂使用增强组件时中心peg骨溶解(伴或不伴植入物偏移)发生率为29%,高于A1使用标准组件的5%(p=0.028)。
  • B2使用增强组件时中心peg骨溶解发生率为10%,与A1使用标准组件无显著差异。
  • 三组术后肩胛盂假体版本角和倾斜角无差异。
  • B3肩胛盂相对病前关节线的假体内移程度大于A1和B2(p<0.001)。

关键数值与推荐

  • 中心peg骨溶解发生率:B3增强组29%,A1标准组5%(p=0.028);B2增强组10%,与A1标准组无显著差异。
  • 假体内移比较:B3组内移程度大于A1和B2组(p<0.001)。

临床怎么用

  • 对于B2型肩胛盂骨缺损,可考虑使用阶梯式增强肩胛盂组件以恢复解剖并取得与无骨缺损者相当的短期疗效。
  • 对于B3型肩胛盂病变,使用该增强组件需警惕中心peg骨溶解风险,应加强影像学随访。

局限性

  • 随访时间较短,中心peg骨溶解的长期临床意义尚需更长时间随访明确。
  • 研究未报告样本量计算、具体P值以外的统计细节及混杂因素控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posterior glenoid bone loss is commonly associated with primary glenohumeral osteoarthritis. Surgical management of bone loss in anatomic total shoulder arthroplasty (aTSA) remains controversial. We studied the use of a stepped augmented glenoid component for management of Walch B2 and B3 glenoids and compared the radiographic and clinical outcomes at short-term follow-up with those achieved with a non-augmented component of the same design in Walch A1 glenoids. METHODS: Ninety-two patients (42 A1, 29 B2, and 21 B3 glenoids) were prospectively followed after aTSA. Sequential 3-dimensional (3D) computed tomography (CT) imaging was performed preoperatively, within 3 months postoperatively with metal artifact reduction (MAR) to define implant position, and at a minimum of 2 years postoperatively with MAR. Scapular 3D registration with implant registration allowed 3D measurement of glenoid implant position, implant shift, and central peg osteolysis (CPO). RESULTS: CPO with or without implant shift occurred in a higher percentage of B3 glenoids treated with the augmented glenoid component (29%) than A1 glenoids treated with a standard component (5%) (p = 0.028). There was no significant difference in the frequency of CPO between B2 glenoids with the augmented component (10%) and A1 glenoids with the standard component. There was no difference in postoperative glenoid component version and inclination between groups. B3 glenoids were associated with more component medialization relative to the premorbid joint line compared with A1 and B2 glenoids (p < 0.001). CONCLUSIONS: A stepped augmented glenoid component can restore premorbid glenoid anatomy in patients with asymmetric biconcave glenoid bone loss (Walch B2), with short-term clinical and radiographic results equivalent to those for patients without glenoid bone loss (Walch A1) treated with a non-augmented component. There is a greater risk of CPO in patients with moderate-to-severe B3 glenoid pathology with this stepped augmented glenoid component. Longer follow-up will help define the clinical implications of CPO over time. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Iannotti JP, Jun BJ, Derwin KA, et al. Stepped Augmented Glenoid Component in Anatomic Total Shoulder Arthroplasty for B2 and B3 Glenoid Pathology: A Study of Early Outcomes. J Bone Joint Surg Am. 2021. PMID: 33989252. doi:10.2106/JBJS.20.01420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。